Literature DB >> 25070601

The clinical analgesic efficacy of buprenorphine.

R B Raffa1, M Haidery, H-M Huang, K Kalladeen, D E Lockstein, H Ono, M J Shope, O A Sowunmi, J K Tran, J V Pergolizzi.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Based on in vitro assays and select animal models, buprenorphine is commonly called a 'partial agonist'. An implication is that it should produce less analgesic effect in humans than so-called 'full agonists' such as morphine or fentanyl. However, buprenorphine has a multimechanistic pharmacology, and thus partial agonism at a specific receptor is not particularly relevant to its overall analgesic action. We review published clinical trials that directly compared the magnitude of buprenorphine's analgesic effect to analgesics commonly considered full agonists. COMMENT: Due to different signal transduction pathways, a drug can be a full agonist on one endpoint and a partial agonist on another. Therefore, we limited the present review to buprenorphine's analgesic effect. WHAT IS NEW AND
CONCLUSION: Twenty-four controlled clinical trials were identified, plus a case report and dose-response curve. Based on complete or comparable pain relief, in buprenorphine had full clinical analgesic efficacy in 25 of the 26 studies.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  buprenorphine; clinical data; efficacy; full agonist; partial agonist

Mesh:

Substances:

Year:  2014        PMID: 25070601     DOI: 10.1111/jcpt.12196

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  20 in total

1.  BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.

Authors:  Norikazu Kiguchi; Huiping Ding; Gerta Cami-Kobeci; Devki D Sukhtankar; Paul W Czoty; Heather B DeLoid; Fang-Chi Hsu; Lawrence Toll; Stephen M Husbands; Mei-Chuan Ko
Journal:  Br J Anaesth       Date:  2019-03-01       Impact factor: 9.166

2.  Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research.

Authors:  Jun-Xu Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

3.  A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.

Authors:  Huiping Ding; Paul W Czoty; Norikazu Kiguchi; Gerta Cami-Kobeci; Devki D Sukhtankar; Michael A Nader; Stephen M Husbands; Mei-Chuan Ko
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

Review 4.  Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.

Authors:  Norikazu Kiguchi; Huiping Ding; Shiroh Kishioka; Mei-Chuan Ko
Journal:  Curr Top Med Chem       Date:  2020       Impact factor: 3.295

Review 5.  Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids.

Authors:  Suhani Dalal; Ahish Chitneni; Amnon A Berger; Vwaire Orhurhu; Bilal Dar; Bennett Kramer; Anvinh Nguyen; John Pruit; Charles Halsted; Alan D Kaye; Jamal Hasoon
Journal:  Health Psychol Res       Date:  2021-08-06

6.  Buprenorphine for Chronic Pain: a Systemic Review.

Authors:  Michael A Fishman; Phillip S Kim
Journal:  Curr Pain Headache Rep       Date:  2018-10-05

7.  Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo.

Authors:  Sylvain Auvity; Sébastien Goutal; Fabien Caillé; Dominique Vodovar; Alain Pruvost; Catriona Wimberley; Claire Leroy; Matteo Tonietto; Michel Bottlaender; Nicolas Tournier
Journal:  Neuropsychopharmacology       Date:  2021-02-18       Impact factor: 7.853

8.  Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids.

Authors:  D E Selley; M L Banks; C M Diester; A M Jali; L P Legakis; E J Santos; S S Negus
Journal:  J Pharmacol Exp Ther       Date:  2020-12-22       Impact factor: 4.030

Review 9.  Opioids and pituitary function: expert opinion.

Authors:  Mônica R Gadelha; Niki Karavitaki; Jeffrey Fudin; Jeffrey J Bettinger; Hershel Raff; Anat Ben-Shlomo
Journal:  Pituitary       Date:  2022-01-23       Impact factor: 4.107

Review 10.  Benefit-Risk Analysis of Buprenorphine for Pain Management.

Authors:  Martin Hale; Mark Garofoli; Robert B Raffa
Journal:  J Pain Res       Date:  2021-05-24       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.